Bayer’s non-hormonal therapy reduces hot flashes in Phase III trials
Bayer’s non-hormonal therapy elinzanetant met primary and secondary endpoints in two pivotal Phase III trials by reducing the frequency and severity of moderate to severe vasomotor symptoms, commonly known as hot flashes, in post-menopausal women. …